Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Symptomatic Aortic Stenosis Clear all
Completed No phase listed Observational
View directory record Official record
Conditions
Aortic Stenosis Symptomatic
Interventions
AVITA--Aortic Valve Improved Treatment Approaches
Behavioral
Lead sponsor
Shared Decision Making Resources
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Georgetown, Maine
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced May 21, 2026, 11:11 PM EDT
Active, not recruiting Not applicable Interventional Results available
View directory record Official record
Conditions
Symptomatic Severe Aortic Stenosis
Interventions
Portico™ NG (Navitor) Valve and FlexNav™ Delivery System, Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Los Angeles, California • Thousand Oaks, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced May 21, 2026, 11:11 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Critical Aortic Stenosis
Interventions
Edwards SAPIEN Transcatheter Heart Valve, Surgical Valve Replacement, medical management and/or balloon aortic valvuloplasty
Device · Other
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced May 21, 2026, 11:11 PM EDT
Not listed Not applicable Interventional Results available
View directory record Official record
Conditions
Aortic Valve Stenosis, Heart Valve Diseases, Heart Diseases, Cardiovascular Diseases, Ventricular Outflow Obstruction
Interventions
JenaValve Pericardial TAVR System
Device
Lead sponsor
JenaValve Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced May 21, 2026, 11:11 PM EDT
Active, not recruiting Not applicable Interventional Results available
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
TAVR with CENTERA THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
23
States / cities
Los Angeles, California • Stanford, California • Loveland, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced May 21, 2026, 11:11 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Symptomatic Severe Aortic Stenosis
Interventions
TAVR Implantation with SAPIEN XT, SAVR Implantation
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
2,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
55
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced May 21, 2026, 11:11 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Symptomatic Severe Aortic Stenosis
Interventions
TAVR
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
19 Years and older
Enrollment
1,074 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
51
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2025 · Synced May 21, 2026, 11:11 PM EDT
Completed No phase listed Observational Results available
View directory record Official record
Conditions
Symptomatic Aortic Stenosis
Interventions
Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
1,127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
37
States / cities
Birmingham, Alabama • San Francisco, California • Hartford, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced May 21, 2026, 11:11 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
TN-201
Genetic
Lead sponsor
Tenaya Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
10
States / cities
La Jolla, California • San Francisco, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced May 21, 2026, 11:11 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
MYK-224
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced May 21, 2026, 11:11 PM EDT
Active, not recruiting Not applicable Interventional Results available
View directory record Official record
Conditions
Symptomatic Aortic Stenosis, Aortic Valve Stenosis, Aortic Valve Replacement
Interventions
Medtronic Evolut PRO, Evolut PRO+ or Evolut FX (where commercially available) TAV Systems, Edwards SAPIEN 3 or SAPIEN 3 Ultra THV Systems
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
18 Years and older
Enrollment
1,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
61
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
CK-3773274 (5 - 15 mg), CK-3773274 (10 - 30 mg), Placebo for CK-3773274
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Evanston, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced May 21, 2026, 11:11 PM EDT
Enrolling by invitation Not applicable Interventional
View directory record Official record
Conditions
Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease, Heart Disease Structural Disorder
Interventions
Navitor Transcatheter Aortic Valve Implantation (TAVI) System, Any Commercially Available Transcatheter Aortic Valve (CAV) System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 11:11 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Transcatheter Aortic Valve Replacement
Procedure
Lead sponsor
The Society of Thoracic Surgeons
Other
Eligibility
18 Years and older
Enrollment
16,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2035
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg), Placebo to match metoprolol succinate
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
28
States / cities
Anchorage, Alaska • Phoenix, Arizona • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced May 21, 2026, 11:11 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Severe Aortic Stenosis
Interventions
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
2,777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • Mountain View, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced May 21, 2026, 11:11 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
Mavacamten, Non-mavacamten symptomatic oHCM therapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
62
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced May 21, 2026, 11:11 PM EDT
Withdrawn No phase listed Observational
View directory record Official record
Conditions
Severe Symptomatic Aortic Stenosis
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced May 21, 2026, 11:11 PM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Aortic Stenosis Symptomatic
Interventions
Siegel Transcatheter Aortic Valve (TAVR)
Device
Lead sponsor
MiRus
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Naples, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
48
States / cities
Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced May 21, 2026, 11:11 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Aortic Stenosis, Coronary Artery Disease, Coronary Stenosis
Interventions
Percutaneous Coronary Intervention (PCI)
Procedure
Lead sponsor
University of British Columbia
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
55
States / cities
Huntsville, Alabama • Phoenix, Arizona • Palo Alto, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced May 21, 2026, 11:11 PM EDT
Enrolling by invitation Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Symptomatic Hypertrophic Cardiomyopathy (HCM)
Interventions
Aficamten (5 - 20 mg)
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
52
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced May 21, 2026, 11:11 PM EDT
Terminated Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Eleclazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2018 · Synced May 21, 2026, 11:11 PM EDT